Quick Takeaways
- Wellington Biomedical Innovation Master Investors (Cayman) II L.P. filed SCHEDULE 13G/A for MBX Biosciences Common Stock (MBX).
- Disclosed ownership: 4.5%.
- Date of event: 30 Sep 2025.
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for MBX Biosciences Common Stock (MBX)
- Reporting Manager
- Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
- Security
- MBX Biosciences Common Stock
- Symbol
- MBX
- Shares outstanding
- 44,830,978 shares
- Disclosed Ownership
- 2,017,394 shares
- Ownership
- 4.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Nov 2025, 18:44:54 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Wellington Biomedical Innovation Master Investors (Cayman) II L.P. disclosed 4.5% ownership in MBX Biosciences Common Stock (MBX) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Nov 2025, 18:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 4.5% | 2,017,394 | 0 | 2,017,394 | Ihsan Speede | Authorized Person |